Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma

Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma

ObjectiveOur study aimed to evaluate the cost-effectiveness of the addition of serplulimab to chemotherapy (cisplatin and fluorouracil) for programmed death-ligand 1 (PD-L1) positive advanced esophageal squamous cell carcinoma (ESCC) as the first-line treatment in China.MethodsA three-state Markov m...

Full description

Bibliographic Details
Main Authors: Hanrui Zheng, Jiafeng Li, Feng Wen, Na Su
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
cost-effectiveness
serplulimab
chemotherapy
esophageal squamous cell carcinoma
programmed cell death protein 1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1216960/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1216960/full

Similar Items